Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) dropped 2.9% during trading on Thursday. The company traded as low as $0.2271 and last traded at $0.2271. 522,121 shares changed hands during mid-day trading, an increase of 12% from the average daily volume of 464,369 shares. The stock had previously closed at $0.2340.
Theriva Biologics Stock Performance
The stock has a market cap of $7.32 million, a P/E ratio of -0.01 and a beta of 1.19. The stock has a fifty day simple moving average of $0.23 and a 200-day simple moving average of $0.26. The company has a quick ratio of 1.13, a current ratio of 1.13 and a debt-to-equity ratio of 0.13.
Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.07) earnings per share for the quarter.
Theriva Biologics Company Profile
Theriva Biologics, Inc is a clinical-stage biotechnology company focused on developing therapies that target the microbiome and tumor microenvironment. Its programs are designed to address serious diseases by using engineered biological products and other approaches intended to improve treatment outcomes.
The company’s development pipeline includes VCN-01, an oncolytic adenovirus being investigated for use in pancreatic ductal adenocarcinoma, as well as microbiome-focused candidates such as SYN-004 (ribaxamase) and SYN-020.
Featured Stories
- Five stocks we like better than Theriva Biologics
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone?
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
- Is Synopsys Back from the Dead? EDA Leader Inks Deals With Amazon and OpenAI
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
